Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats. Issue 5 (May 2014)

• Record Type: Journal Article
• Authors: Lin, Han‐Chieh; Huang, Yi‐Tsau; Yang, Ying‐Ying; Lee, Pei‐Chang; Hwang, Lih‐Hwa; Lee, Wei‐Ping; Kuo, Ying‐Ju; Lee, Kuei‐Chuan; Hsieh, Yun‐Cheng; Liu, Ren‐Shyan
• Is Part Of: Journal of gastroenterology and hepatology. Volume 29:Issue 5(2014:May)
• Page Start: 1073
• Page End: 1082
• Publication Date: 2014-05
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.12480
• Languages: English
• ISSNs: 0815-9319

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jgh12480-sec-0001" sec-type="section"> <title>Background and Aim</title> <p>Vascular endothelial (VEGF) and fibroblast growth factor (FGF)‐induced hepatic stellate (HSCs) and liver endothelial cells (LECs) activation accelerates hepatic fibrogenesis and angiogenesis, and hemodynamic dysarrangements in cirrhosis. VEGF targeting agents had been reported as potential drugs for cirrhosis. However, the evaluation of effects of dual VEGF/FGF targeting agent in cirrhosis is still limited.</p> </sec> <sec id="jgh12480-sec-0002" sec-type="section"> <title>Methods</title> <p>Using hemodynamic parameters, blood chemistry, primary isolated HSCs and LECs, histology, and digital imaging, we assess the effects of 2‐week brivanib alaninate, a dual VEGFR/FGFR inhibitor, treatment in the pathophysiology of bile duct‐ligated‐cirrhotic rats.</p> </sec> <sec id="jgh12480-sec-0003" sec-type="section"> <title>Results</title> <p>Fibrogenic and angiogenic markers in the serum and liver of bile duct‐ligated‐cirrhotic rats, including hydroxyproline, transforming growth factor‐β1, angiopoietin‐1, VEGF, FGF‐2, endocan and phosphorylated‐VEGFR2/VEGFR2, and phosphorylated‐FGFR/FGFR together with hepatic CD31/angiopoietin‐1 expressions (immunohistochemistry staining), angiogenesis (micro‐computed tomography scan), microcirculatory dysfunction (<italic>in vivo</italic> miscroscopy and <italic>in situ</italic> liver perfusion study), portal hypertension, and hyperdynamic circulations (colored microsphere methods) were markedly suppressed and ameliorated by brivanib alaninate treatment. In <italic>in vitro</italic> study, acute brivanib alaninate incubation inhibited the transforming growth factor‐β1‐induced HSCs contraction/migration and VEGF‐induced LECs angiogenesis. Concomitantly, the overexpression of various fibrogenic and angiogenic markers in HSCs and LECs, and in their culture media, was increased in parallel and these changes were suppressed by acute brivanib alaninate incubation.</p> </sec> <sec id="jgh12480-sec-0004" sec-type="section"> <title>Conclusions</title> <p>This study demonstrated that brivanib alaninate targeting multiple mechanisms and working in the different pathogenic steps of the complications of cirrhotic rats with portal hypertension.</p> </sec> </abstract>